A financing round helps accroma labtec to meet market’s growing demand

Even today, in modern laboratories, for lack of alternatives, manual work is still used for many jobs. This work is prone to errors and ties up well qualified employees in the wrong place. However, nobody has yet managed to copy or improve human flexibility and handling of the specific samples.

A company based in Muttenz changes this. Accroma Labtec has succeeded in developing a simple system for automated sample preparation, which is flexible (no large number of samples required), works very fast (can perform different steps in parallel) and has solved known problems such as carry-over, heat effects or long set-up times. The secret lies in the accroTubes developed by accroma labtec, a consumable that lays the foundation for the flexibility and processing speed of the robot.

The company works with tier-one clients such as Novartis, Syngenta, AstraZeneca and has a global distribution network covering Europe, North America, the middle east, and Asia. Q1 2021 resulted in a positive momentum with a yearly increase of >100% in terms of sales.

A new financing round will now accelerate the company’s business development processes. This pre-Series A round is funded by a diversified group of new investors as well as all current shareholders that decided to follow-up on their first investments. The purpose of this funding round is to meet the growing demand to prepare the company for a large Series A that will take place in Q3 2021. Accroma Labtec Ltd. collaborated with BV4 Ltd. as a strategic fundraising advisor for this pre-Series A and the collaboration will continue towards the Series A. The company is expected to raise a Series A round of CHF 3.0m in Q3 2021 to expand its team and scale internationally. 

Stefan Gafner, CEO of accroma labtec comments: “This fresh increase of capital will permit us to meet our growing demand and accelerate our growth. We are very pleased that our past shareholders decided to follow-up and that we onboarded new investors that bring smart money to the table. We look forward to our Series A that will allow accroma labtec Ltd. to accelerate its scale-up process.”